secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-277662
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics Q3 2025 net loss $9.4M, cash $65.1M; Chagas Phase 1 ongoing
----------------------------------------------------------------------------

- Net loss of $9.4M vs $12.7M in Q3 2024, R&D expense $7.0M (down from $8.3M), G&A $3.0M.
- Cash, equivalents and investments $65.1M at Sept 30, 2025; projected runway into 2028.
- Chagas Phase 1 of oral AN2-502998 advancing; data expected Q1 2026, Phase 2 start in 2026.
- M. abscessus program: IIT expected to begin enrollment early 2026, pending regulatory clearance.
- Collaboration with GSK on boron-based TB drugs, with third-year Gates Foundation funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312525277662/0001193125-25-277662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312525277662/antx-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-277662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer